NCT05873959View on ClinicalTrials.gov

An Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular Trauma

CompletedOBSERVATIONAL
Enrollment

17

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

May 26, 2023

Study Completion Date

January 15, 2024

Conditions
TraumaTrauma InjuryTrauma, MultipleTrauma Blunt
Interventions
BIOLOGICAL

HAV implantation

HAVs already implanted under humanitarian aid program to repair or reconstruct arteries following an extremity life- or limb-threatening traumatic injury.

Trial Locations (3)

Unknown

"Municipal Non-Profit Enterprise City Clinical Hospital #16 of the Dnipro City Council", Dnipro

"Medical Center LLC CLINIC VERUM EXPERT", Kyiv

"Communal non-profit enterprise Vinnytsia Regional Clinical Hospital named after E. Pirogov of the Vinnytsia Regional Council, center of cardiovascular surgery", Vinnytsia

Sponsors

Lead Sponsor

Humacyte, Inc.
All Listed Sponsors
lead

Humacyte, Inc.

INDUSTRY

NCT05873959 - An Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular Trauma | Biotech Hunter | Biotech Hunter